Showing results (61-70 of 753) with videos related to
Sort By:
Pageof 76
European Heart Journal. Quality of Care & Clinical Outcomes|August 3, 2024
The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetesElla Zomer, Jennifer Zhou, Adam J Nelson, et al.Current Opinion in Lipidology|September 23, 2017
Implications of GLAGOV studyStephen J Nicholls, Rishi PuriAmerican Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 20, 2018
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging DrugsKohei Takata, Stephen J NichollsDrugs of Today (Barcelona, Spain : 1998)|January 13, 2009
Atherosclerotic plaque reduction: blood pressure, dyslipidemia, atherothrombosisSatish Arora, Stephen J NichollsCurrent Medicinal Chemistry|June 22, 2006
Emerging role of intravascular ultrasound in the assessment of experimental anti-atherosclerotic therapiesStephen J Nicholls, Ilke SipahiCurrent Cardiology Reports|June 24, 2017
PCSK9 Inhibitors: Treating the Right Patients in Daily PracticePeta King, Stephen J NichollsCurrent Atherosclerosis Reports|April 29, 2010
Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?Kiyoko Uno, Stephen J NichollsFuture Cardiology|September 26, 2015
Men and women--similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists CollaborationLeonard Kritharides, Stephen J NichollsDiabetes & Vascular Disease Research|March 13, 2012
Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetesStephen J Nicholls, Kiyoko UnoExpert Review of Cardiovascular Therapy|October 31, 2014
Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerabilityYu Kataoka, Stephen J NichollsPageof 76